<SEC-DOCUMENT>0001144204-12-045975.txt : 20120814
<SEC-HEADER>0001144204-12-045975.hdr.sgml : 20120814
<ACCEPTANCE-DATETIME>20120814172211
ACCESSION NUMBER:		0001144204-12-045975
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120814
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120814
DATE AS OF CHANGE:		20120814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		121034411

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v321307_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
August 14, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SYNTHETIC BIOLOGICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">Nevada</TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">1-12584</TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">13-3808303</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">(Commission File No.)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">617 Detroit Street, Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ann Arbor, Michigan 48104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (734) 332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02 &ndash; Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 14, 2012, Synthetic Biologics, Inc., a Nevada corporation
(the &ldquo;Registrant&quot;) issued the attached press release that included financial information for its second quarter ended
June 30, 2012. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained in
the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant&rsquo;s
registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: right">(d)&nbsp;&nbsp;</TD>
    <TD STYLE="width: 96%">Exhibits.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc. dated August 14, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 50%; padding-right: 0.8pt">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="padding-right: 0.8pt">Date: August 14, 2012</TD>
    <TD STYLE="padding-right: 0.8pt">By: <U>/s/ C. Evan Ballantyne</U></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Name: C. Evan Ballantyne</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Title: Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.2pt; text-decoration: underline"><U>Exhibit No .</U></TD>
    <TD STYLE="width: 90%; padding-right: 0.2pt; text-decoration: underline"><U>Exhibits.</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.2pt; text-align: center">99.1</TD>
    <TD STYLE="padding-right: 0.2pt">Press Release issued by Synthetic Biologics, Inc. dated August 14, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v321307_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports Second Quarter
2012 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">-- Addition of Monoclonal Antibodies
for Infectious Diseases Emphasizes Focus on Synthetic Biologics --</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ann Arbor, MI, August 14, 2012 &ndash;</B>
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for unmet medical needs,
today reported financial results for the three and six months ended June 30, 2012 and summarized operational highlights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operational Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expanding Synthetic Biologic Programs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Enhanced our relationship with Intrexon by entering into a second worldwide exclusive channel collaboration
for the development and commercialization of a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious
diseases not adequately addressed by existing therapies. Utilizing Intrexon&rsquo;s comprehensive suite of proprietary technologies,
initial discovery efforts will target three infectious disease indications.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Initiated preclinical research for the development of a synthetic DNA-based therapy for pulmonary
arterial hypertension (PAH), utilizing the UltraVector&reg; platform and RheoSwitch Therapeutic System&reg; of our collaborator,
Intrexon.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Appointed biologics expert and gene therapy veteran, Michael Kaleko, M.D., Ph.D., to serve as Scientific
Director. Dr. Kaleko has worked in the field of gene therapy since its inception in the mid-1980s and has extensive experience
developing vector platforms, inducible transcription systems and product candidates in multiple disease areas.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Advancing Clinical Trial Programs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Strengthened our clinical and regulatory functions by recruiting the former Chief Medical Officer
of Clinical Data, Inc., Carol Reed, M.D., to serve as Senior Vice President of Clinical &amp; Regulatory Affairs. Dr. Reed, who
led the design and management of two consecutive successful Phase III clinical trials and FDA approval for VIIBRYD&reg;, is responsible
for the design and implementation of all aspects of clinical development and clinical trials, as well as regulatory initiatives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completed enrollment of 164 patients in
a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial evaluating the efficacy and safety of our
proprietary oral formulation of estriol (Trimesta&trade;) for the treatment of relapsing-remitting multiple sclerosis (MS) in women.
According to various reports, sales of oral disease-modifying therapies for MS, of which Trimesta&trade;, if and when approved,
would be in a drug class, is expected to reach $5 billion annually by 2017.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiated patient enrollment in a second
randomized, double-blind, placebo-controlled Phase II clinical trial of Trimesta&trade;<SUP> </SUP>for the treatment of cognitive
dysfunction in MS. Charitable organizations have pledged to financially support a majority of this new MS clinical trial. As of
August 1, 2012, 11 of 64 patients have been enrolled into this trial and patient recruitment continues.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Board of Directors &ndash; Improved
Corporate Governance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Improved corporate governance and strengthened the Board by separating the roles of Chairman and
Chief Executive Officer with the appointment of Jeffrey J. Kraws to serve as independent, non-executive Chairman of the Board.
Mr. Kraws has served on the Board of Directors since January 2006.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: yellow">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We continue to broaden our reach
within the synthetic biologics area as evidenced by the recent expansion of our relationship with Intrexon for the development
of monoclonal antibodies to treat infectious diseases. These discovery programs enhance our product pipeline and further emphasize
our commitment to the development of new treatment options for unmet medical needs,&rdquo; said Jeffrey Riley, Chief Executive
Officer of Synthetic Biologics. &ldquo;We look forward to announcing more about our infectious disease targets and program progress
in the near future.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Three and Six Months Ended June 30, 2012 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of management&rsquo;s plan to streamline
our focus, we sold the clinical reference lab on March 8, 2012. Laboratory revenues for the three and six months ended June 30,
2012 and June 30, 2011 were charged to discontinued operations, resulting in no revenues for these periods. In addition, the gain
on the sale of the clinical reference lab of $677,000 was included in discontinued operations for the six months ended June 30,
2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses were
$1.2 million and $2.6 million for the three and six months ended June 30, 2012, respectively, compared to $524,000 and $1.8 million
for the same periods in 2011. These increases of 124% and 50%, respectively, are primarily the result of additional employee costs,
the expansion of our investor relation activities and legal fees related to various Securities and Exchange Commission filings.
Charges related to stock-based compensation were $287,000 and $786,000 for the three and six months ended June 30, 2012, respectively,
compared to $51,000 and $810,000 for the same periods in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses were
$547,000 and $933,000 for the three and six months ended June 30, 2012, respectively, compared to $281,000 and $512,000 for the
same periods in 2011. These increases of 95% and 82%, respectively, are primarily the result of additional employee costs and increased
program costs associated with our expanded pipeline, including the initiation of our preclinical program for the treatment of PAH
and our clinical trial for the treatment of cognitive dysfunction in MS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $7,000 for the three months
ended June 30, 2012, compared to other expense of $761,000 for the same period in 2011. Other income was $12,000 for the six months
ended June 30, 2012, compared to other expense of $1.5 million for the same period in 2011. Other expense for the three and six
months ended June 30, 2011 included $760,000 and $1.6 million, respectively, relating to the estimated fair value of the warrants
associated with the January 2011 and April 2011 financings, adjusted for the change in their fair value at the end of each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash at June 30, 2012 was $5.9 million
compared to $6.7 million at December 31, 2011. As of July 31, 2012, we had approximately $5.6 million in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics is a biotechnology
company focused on the development of product candidates to address serious diseases and unmet medical needs. Synthetic Biologics
is developing the following synthetic biologic candidates: a series of monoclonal antibodies (mAbs) for the treatment of serious
infectious diseases not adequately addressed by existing therapies and a synthetic DNA-based therapy for the treatment of pulmonary
arterial hypertension (PAH). The Company is also developing drug candidates for the treatment of relapsing-remitting multiple sclerosis
(MS), cognitive dysfunction in MS, amyotrophic lateral sclerosis (ALS) and fibromyalgia (partnered with Meda AB). For more information,
please visit Synthetic Biologics&rsquo; website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UltraVector&reg; and RheoSwitch Therapeutic
System&reg; are registered trademarks of Intrexon Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements on Synthetic Biologics&rsquo; current expectations and projections about future events. In some cases forward-looking
statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
&quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements regarding our continued focus of our
efforts in the field of synthetic biology and advancing our clinical programs and the expected size of the future market for sales
of oral disease-modifying therapies for MS. The forward-looking statements are subject to risks and uncertainties that could cause
actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could
cause actual results to differ materially from those reflected in Synthetic Biologics&rsquo; forward-looking statements include,
among others, a failure to receive the necessary regulatory approvals for commercialization of our therapeutics, a failure of our
clinical trials to be commenced or completed on time or to achieve desired results, a failure of our clinical trials to receive
anticipated funding, a failure of gene therapy to receive market acceptance, a failure of our monoclonal antibodies for the treatment
of infectious diseases to be successfully developed or commercialized, our inability to maintain our licensing agreements, including
our agreement with Intrexon, or a failure by us or our strategic partners to successfully commercialize products and other factors
described in Synthetic Biologics&rsquo; report on Form 10-K/A for the year ended December 31, 2011 and any other filings with the
SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation
to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables to Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-size: 10pt; font-weight: bold">Synthetic Biologics, Inc. and Subsidiaries</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-size: 10pt; font-weight: bold; font-style: italic">(in thousands, except share data)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Condensed Consolidated Balance Sheets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">(Audited)</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font-size: 10pt">&nbsp;&nbsp;Cash</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,932</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,678</TD><TD STYLE="width: 29%; font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;Accounts receivable, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">245</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">405</TD><TD STYLE="font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;&nbsp;Other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">94</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;Assets of discontinued operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23</TD><TD STYLE="font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;Property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">254</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">323</TD><TD STYLE="font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;Long-term note receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;Deposits and other assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">31</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,245</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;Current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">395</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">417</TD><TD STYLE="font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;Stockholders' equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,850</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,059</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders' equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,245</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; background-color: White">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font-size: 10pt; font-weight: bold">Condensed Consolidated Statements of Operations (Unaudited)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the six months ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left">&nbsp;&nbsp;General and administrative</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,176</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">524</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,644</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,757</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;Research and development</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">547</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">281</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">933</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">512</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs and expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,723</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">805</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,577</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,269</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from Continuing Operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,723</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(805</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,577</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,269</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Other Income (Expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;Warrant expense </TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(776</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,492</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(78</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;Other income (expense)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">50</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total other income (expense), net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(761</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,520</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Loss from Continuing Operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,716</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,566</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,565</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,789</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Income (Loss) from Discontinued Operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(156</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(114</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">493</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(77</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss and Comprehensive Loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,872</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,680</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,072</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,866</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net Income (Loss) Per Share - Basic and Dilutive</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;Continuing Operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.05</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.06</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.11</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.14</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;Discontinued Operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.02</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Net Loss Per Share</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">33,011,460</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">27,885,479</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">32,507,312</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">26,560,448</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kris Maly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President of Corporate Communication</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(734) 332-7800, Ext. 22</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">###</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!L`C,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MD\P9(W#(]ZBO-2M].MS-<7$,$0ZO(X11^)XI@+P!C(ICMM`(Z'O7':Q\>_!^
MBMY<WB&Q=_2%FF/_`)#!K'\7?M->$O!?@N77KF_EAL!_JR\,L<EV?^F*,,O_
M`,!S7)B<5##T76KM12+P^&JUY*E13;?;<]*,BXSO'7'7C.<4-$W'S'\37@^A
M?\%#?AGJMO`TVKW-C)<#>8Y=/N,QG&<%U7`YKT#PK^T?X$\8`IIOBG09G[Q?
M:HXY!_P$D']*\W!\0Y;B?X=>,OFCOKY#F%+^+1DOD_\`([^BHK>_@NUW1312
MCU1PP_2G^:N0-RY/3GK7M1J1DKQ=T><TT[,=133*HZLOYT[<!U-4(**-WO2;
MQZB@+BT444`%%%%`!112>8N2-PRO)YZ4`+GWI-X&,D<]/>N8^)_Q>\*?!3PR
M^L^+_$>B>%M)5PHN]4OXK2*1ST4-(P!8^@.37ROXW_X+V_LP^"KF:VB\=WNM
MW$8^==-T2]E0_P"Z[Q+&?P:@#[/:0("2P&WKD]*!*K`$,#DXZU\:>"/^"]W[
M+OC.[M[4_$"YT6YG'RIJ.BWD"I_O.L31K^+5].?"3XX>#_CSX9&L>#/%&A^*
MM-#%'NM+OHKM(7'5&\LD*WL>:`.PHKBOC+\?_!7[/6@6^I^.O%.A^$["_G%M
M!<ZK=):Q22D9$89B`6(!P`<FO._^'GW[/)V_\7I^')W9Q_Q.H><#/][TH`]X
M>01KEF`'J3@4M<I\)_C/X5^.GA!=>\'^)-(\3Z,[O$-0TRZCN("Z$AEW*2N5
M((([$&NKH`*0.&&00?QI=PSC/(KRGXI?MN?"#X&>+)=!\8_$SP9X;UR!%DEL
M=1U:*&>-6&Y6,;,&`(Y!(Y%`'JU!;`))Z5X1'_P4Y_9YFE5$^-'PY=W9451K
M4)+,V<*!NZG!P.^#6GX__;\^"GPD\87?A_Q/\4O!6A:]IK!+NPOM8BAN+=BH
M8!XW8,I(93R.A'K0![$\JQ_>91]3BG5X]\-?V]?@O\8/&%GX<\+?%+P/KVN:
M@66TL++6(9)[DJ,L$4,68@<G`.*]AW#CG[W3WH`*,].>M%>>_&O]IOX>?LY#
M2QX]\8^&O"']LF3[%_:U[%:?:?+V^9LW,-VS>F[&<;USU%`'H1..2:02JW1@
M?QKP_0?^"D?P%\4Z[9Z9IGQA^'U]J6IS)!:V\.KPR23RLP58U4-EF8D``<DD
M"M+XF?MV_!KX.^-+SPSXM^)W@KPYKVF;/M6G:AJT4-Q#O19$W*S!AE&5AD<A
M@>A%`'K]%>#?\/0/V=O^BU_#?_P>0_\`Q5'_``]`_9V_Z+7\-_\`P>0__%4`
M>\T5X-_P]`_9V_Z+7\-__!Y#_P#%4?\`#T#]G;_HM?PW_P#!Y#_\50![SG/>
M@MM!).`*\;^'?[?'P5^+7C*R\-^&?BEX*U[7-58I:6%AJ\4L\[!2Q"*K%F("
ML>.P)[5!XL_X*&?`SX>>*=1T37OBQX#TC6M)F:WO+.ZUB*.:WD4X9'1FRK`\
M$'D&@#VHN%&20/QI:\N^$G[9_P`)OC]XG;1/!/Q&\(^*M92%K@V>F:I'<3"-
M2`S[%).T%E!.,`D>M>HT`%('##((/XTM>7?%O]L_X3?`'Q.NB>-OB-X1\+:R
M\*W`L]3U2.WF,;$A7V,0=I*L`<8)!]*`/40VX`@Y!I"X&,D<]/>O%?"?_!0S
MX&?$/Q3IVB:%\6/`>KZUJTRV]G9VNL1237$C'"HB*V68G@`<DUT_QN_:G^'/
M[.L^G0^//&_AGPA+JRN]HFK:DEHUPJ8#E`Q!8*64$CID>M`'HE%>#?\`#T#]
MG;_HM?PW_P#!Y#_\51_P]`_9V_Z+7\-__!Y#_P#%4`>\T5X-_P`/0/V=O^BU
M_#?_`,'D/_Q5'_#T#]G;_HM?PW_\'D/_`,50![P95&<L./>EKQ_0/V[?@WXJ
M\%^(?$NF_$[P7>Z#X1\C^VM2BU>%[?2_M+E(/-8,57>X*KNZD$#)K&_X>@?L
M[?\`1:_AO_X/(?\`XJ@#WFBO!O\`AZ!^SM_T6OX;_P#@\A_^*H_X>@?L[?\`
M1:_AO_X/(?\`XJ@#WFBO!O\`AZ!^SM_T6OX;_P#@\A_^*H_X>@?L[?\`1:_A
MO_X/(?\`XJ@#WCS!_>'YTM>=Q?M6_#F?X+2?$=/'/AA_`<3;'\0+?(=/1O-$
M.#+G:#YI$?7[Y"]>*XK_`(>@?L[?]%K^&_\`X/(?_BJ`/>#(JY)8<=>>E+7-
M_#+XG^'OC'X(L_$OA36M/\1:'J>_[/J6GS)-;S[':-MCJ2K;75E.#P5(Z@BN
MCWC)&1D4`+N]Z3>"Q7()';/-8?COXC>'_A;X=EUCQ/KVC>'-)@_UE[JE[%9V
MT?UDD8*/Q-?*_P`0O^"['[,/@*:6U;XC#6IXA_J]*TB[N8W^DGE^6?\`OJ@#
M[$5PZ@@A@>XY%(95522R@`X)SP*^*O!?_!?3]F#QA>PP2>-[W19YONG4]!NX
MT/\`OR)&ZK^)%?4OPC^.W@WX]>&_[7\%>*M!\5:>C['GTJ^BN5AD_N2;&.UO
M8X-`'944;AG&>?2B@`HHHH`*;)<)$A9W5552Q)(``'4_2G5X3^UU\7I=`TR#
MP_82R037\8ENID)!BC_A3V)[^U,"/XN_M<1Z+<2Z;X62&[DA'SWK,&A7_<`^
M_P#A7ANJZYX@^)FHE[B\O-0E<[<NY(B/H>BBJ/ASPS/XFU.&UA+*6^^P'"_7
MTKZ3^"?P7LX].BN)HO\`0XE_=1L,&;_;)[CWK;1`>5>$?V;=7\3#<Y8^T*DQ
M_P#?;X%>@^*OV.;+XIV5C'XIBBU)]-@^SVTWGR)<PQ_W-RA5)]\5[G#`+>W"
MJN%'\*IMJ3!V]#7G9AA:&+HRH5X<T)=#HPF+K8:M&O0GRRCU1\D:[_P3&T\:
MC"-/NXQ:/_K-X?SHOH=V#7/:]_P2SN4C/V+4K:8'^"5BI/X[#7VK&KCKN/UI
MV#CH21ZBOS;$>$?#\N><82BWVD]/0^OH^(_$$=)5;^J3/S^_X9?^+WP/F$V@
M:MJL,</^J^S22-$WU1&;_P!`KM+G]MKQ]^S_`/"CPU>^*-$F\6W.KW-TD[@B
M"2.&/R<'*)M_C?\`@_A;T-?9$<'G(%DB#`>HKGOB!\,M&^(>EBWUG28-0C4-
MM#)\T>?O;6`W#/M7M<)\$+)LQ>)>)G4I/[#>A&.XQAF-*$<=0A=;RBK,\W^`
MO[>_P]^.TL-E8ZN=-UB7@:=J(6"8GT0YV/\`\!)KVQ)48`APV3CKFOCGX_\`
M_!+O3O$D4VH>&+B1+L?.(?,,<V?:08#'_>Q7D_@+]IWXL?L8ZK_8OB6WO?%G
MAFTD\J2WO6VW5LO^P<9Q_LGY/>OU&>6TJRY\+*_D<4\HP^(ASY=.[_E>Y^D.
M><9YQFC%>9?L_P#[3_A/]I'PX+[P[J0>>+!N+.4A+FV)'`D0G<1Z8%>EO+MY
MSG'->5.,HNTE8^:K471=JBU)J*-WO1N`ZFH)N%%%%`!7SI_P4J_;MTO_`()]
M_LXWWC&XMEU/6KN4V&AZ;Y@'VVZ<9!;TC3JQ[#KC-?1=?C%_P=+^);Z?XF?"
M+1S-*FE6VF:C=Q(N=AGDD@1G/KM6.,CT#2'UH`_.']H_]J;QW^UM\2KOQ/X\
M\176O:I,VW8YVVUC&3A4BB!VQQ@D?=!-7O@E^P_\7/VC--6_\%?#GQ=XCTUV
MVK?6^ER/:D^@N"OEY_&N3^#,6A7/Q>\)P^*"\7A676+--7+'`%FUP@G.$Y&%
MR?H,U_5QX+LM#M_"FF1>&ETTZ$EJ%T]=.\L6RVY'R^48_E\L@#E<T`?RT?&7
M]DSXI_L[VR3>./A_XR\)6<K;$N=0TR>"U8^@FV!2?QK(^!/Q]\8_LV^/[7Q5
MX"\1:KX>UJR<"*YLIU5)@.J/$S;)$/\`SR<`>]?U9^*_!VD^/_#=_HVMZ9::
MMI.J0FVN;2\B2:"ZB_N,IX9>>_-?S\_M'?\`!#7XZ^'?C[XOL_`?PXU/7?`]
MOJMQ_85Z-0MVWV1DW0$F28.6"\'B@#]*/V9/C7X7_P""Z?\`P3V\2>%_%=A%
MI7B2`"PUJ*W82?V=>["UMJ,()W"-F#D+U)1X\E037X5?'SX'>(OV;OC#XB\#
M^+;&2PUWPW>&SGA`(24[05E0GK&Z$,K#@@@C(K]7_P#@@A^PQ\=_V-_VH?%-
MQX\\#:GX:\)^(_#DD,DTEY;R1->)<6[0G9'(_(3[2/\`@==G_P`'$/\`P3S7
MXQ_#"'XU^%['S/$?@RW\O7HX8\G4=,R0)L#EG@W,<X^Y(23A.`#X_P#^"!?_
M``4(/[+/[0J_#OQ)?^5X$^(TT<*M/(!%I6H@!8+@$G"HZ@1OT``C8_<:OW[,
MJA2Q9<#C.>.N/YU_(2Q:$LS;@V]F'[S]X&'W6!7[N*_H7_X(?_\`!0D_MI_L
MQ6^AZ]>^?\0O`,<6GZJ7(\W4+?&V&\']XE1\^!P_!Y-`'T/^V1^U)X?_`&,O
MV=O$OQ`\0.K0:-;L;.TW8;4;B0A8H%SU+RE0<?=!S7\POQJ^,NN_M!?%?7_&
M_B:]DO-=\1WSWUW)G*H6/W4'\*QIP%[5]K_\%]/^"A+?M1?M$M\/O#5_YO@7
MX<320DQ2#RM5U$@K/<$CAD128T[$&1A]]*^//V:OV?O$O[57QO\`#?@+PQ"+
MK6->N4@1_+)6")5+O+)C[J1J"Q8\$#-`'VS_`,&^O_!.X?M&?'-_BIXJL1)X
M/^']R#I\<T9:+5M5P&12#P\<"A9#C(W>6I^XXKQ#_@M@X'_!4?XMY4G&HVV>
M/^G*U/\`*OZ#/V7?V<-`_90^!GAGX?\`ABT,&D>';06RRE=LMW(3F2>3'5Y&
M^<D]"=OH*_GS_P""V'_*4;XP?]A&W_\`3?:T`?./@'QSJWPN\;:1XAT+4)],
MUG0[J'4+*Y@8AK:6,Y#9'7#<%?XEK^E[_@FW^V]IG[>W[+^D>,;?[';Z]`1I
M_B#3X>#I]\J@N`#SM9"'4GJK`C(K^8E@4V[LC=R,\9Y`_FRCZL/45]4_\$C/
M^"@UQ^P1^U%;:CJ%S=GP-XFV:;XBM@2RQP[B4N47_GI$Y9R>ZF1?XDH`_I3W
M>]?D#_P=7G;_`,*'S_U,/_N+K]<M,U>UUK3K:\L[JWN[2\B6>">&19(YXV`9
M75APRD$$$<$$5^1G_!UOT^`WT\0_^XN@#\R/V-O^3N/A5_V-NE?^ED%>\?\`
M!>8[_P#@J[\52.0!I9XYZ:/9#^8/Y5X/^QM_R=Q\*O\`L;=*_P#2R"OZB=8^
M"_A+Q)JDU_JGA70-3O[@J9KF\TR">9\*JKEBI)PJ@4`?R84AD"M@L`<@8SSR
M`1^8(/T(K^LW_AG[P%_T)'A+_P`$MO\`_$5_/U_P7F\/6'A#_@I=XQT[3+&Q
MTVR2QTQE@M;<0QQ.;.!F8*`!R:`/CC!YZ\''Z$_R!/T!HKZ<_P""->B6GB?_
M`(*8?"NQU&RL[W3[B]N8Y+>YC$L;[;*=AE3PW0_E7]&'_#/W@+_H2/"7_@EM
M_P#XB@#^=C_@BF"/^"H?P@8YP+^X.>W_`!YW/_Q2_F/6N/\`^"H'_*1#XS^W
MBW4<^W^D?_6-?TN:1\%/"'AO5H]0T[PGX=L;VW?S(I[;3((I4)7:=K!01Q[U
M_-)_P4__`.4A_P`;/^QMU#_TH>@#Z1_X-I_^4B%Y_P!BEJ/_`*46M?OK7X%?
M\&U`(_X*'7C'./\`A$M1.>W_`!\6U?OIO'J*`%K\"O\`@Y8_Y2(6?_8I:=_Z
M475?OIO'J*_`O_@Y7!/_``4.LVY(_P"$2TXY[?\`'Q<T`?-O_!+_`/Y2(?!C
MW\6Z=CW_`-(_^N*^\?\`@ZG_`.1_^#/_`&#M5_\`1EK7P?\`\$P/^4A_P3_[
M&W3_`/TH2OO#_@ZG_P"1_P#@S_V#M5_]&6M`'Y-%2,$@_-@CWR<?SI*V/A_!
M%)XWT2.7$JO?1*RM]UU,G"U_5I_PS]X"_P"A(\)?^"6W_P#B*`/Y,Z*_K,_X
M9^\!?]"1X2_\$MO_`/$4?\,_>`O^A(\)?^"6W_\`B*`/Y\?V.01_P2?_`&TB
M<\?\(3_Z>)C_`"(/XBOD&OZSHO@SX2L=,O=/M_"WAZWLM1V?:;5--MT@O3&V
MZ/S%"X;8W*YZ=:;_`,,_>`O^A(\)?^"6W_\`B*`/Y-`C,2,$D=>.G('\R!^(
MI*_H5_X+A_!KPEX8_P""7'Q1U'3O"WA_3+^V&F>3<6>F6\,T6=6M%^5@F1E6
M(-?SU4`*492`0<GIQUY(_F"/P-)7]"O_``0\^#7A+Q/_`,$N/A=J.I>%O#^J
M7]R-3\ZXO-,MYII<:M=K\S%,G"J`*^M_^&?O`7_0D>$O_!+;_P#Q%`'Y+^&'
M`_X-6]>!(R-0B)]L^)[<C\P0?H17Y-U_19_P7$\-6'A3_@D?\4K'2;*STRPC
M?2'6"UMUAC0G6[)F(4`#GV%?SIT`?T>?\$&6S_P2@^%1SG_D*_\`IXO:TO\`
M@J%_P4U\._\`!.GX2Q73PVVL^-]?#0:'HYR%D.<-<2D?=@0]1P7/"Y.:P_\`
M@ACJ\.A?\$BOAC?7SI!;6T6KS2NQ"I$BZO?%G8G@*`,DG@`5^&/[?G[66H?M
MM?M5>*?B!>-<"ROKG[-I%M(Y#6&GJ,0QJ.@8KRY[-UYH`P?VF_VO_B%^UYXZ
MN->\?^*+_7+J2;?#;/(Z65BN<8@B3B/GV-<;X2\#ZWX^U8:?H6CZKK=^3@6U
MA:27,Q/IM0$_I7TM_P`$F/\`@G/=?\%$?VA&T[4I[RP\"^%XH[W7[BV(1G61
MV,5HK$?>E".3W`1CV-?T/_!7X(>%?V>_!-KX;\%^&=-\,:#8Y6.TLHEC5NGS
MMU:1O]ISNXH`_E3\<?"_Q-\,;L6_B7P[KOAZ=ND>IV$MHY_"10:N_!3XY^,_
MV=_'-MXF\#>(=7\,:O9$8N+&Z:,LI'"2+S&8R/\`ED?E]Z_JL^(WPI\/_&+P
MI<Z#XLT'2O$6BW8_?66H6Z7$+_\``&!`_.OY\?\`@LY_P3:L_P!@3]H.QG\,
M).W@+QG')=:1%(3(^FS*0+BW+M\S*%(*GT84`?JQ_P`$B?\`@JI9?\%"/A]=
MZ/XABLM)^)7AJ%9M2LX/W=O?0;@/MMN&YP"P#K_"2`>HK[<K^6__`()X?M&W
M?[+'[:/P[\96]S/#:66IPV^J`'"RV$SF*X1AW"P&1_9UC[XK^I"@`HHHH`*^
M+_VE-5EU+XTZY)*2WD.MO&O\(")U_.OM"OC']IS2FTGXW:PC9VW16X7C[RO'
MU'J-W&?7BM:3U`O_``8T?&BR71!\VZG*(?0#J?I7UEI6G1:3IUM:1C$<*>4/
M3Z5\L?">Z\WP@@0X,$\@^A(SC\J^J='U.+6-,@NDQMG42`9Z558/,MT4;O>C
M-87`****`"BBB@"%1A1@"N3^)?P<T;XN:.]IJ]KYP;E9<*LD1_V#C(_&NM4'
MDX;CVI0#Z'\JTC5G!\\'9ETZ\X3]I3E8_-C]HG]D+Q3^RWXRA\5>#;R\T][8
MD6]U9L5\Q3U0C[JY_B1OD;^$U]`?L4_\%!=.^/4T7AKQ5';Z-XUA_=C<"L6I
ML.ICS]UQW0\U]*>)?#UIXJTB6PO;2.ZMK@%9(W7(8?7L:_-3]LW]F6?P#XYG
MU#2+;6--FMF$UG)*@26;']R2-\,R>@Y:O;P\Z6/I^QKZ3[GUV%K8?-:7U?$:
M5%M(_3TNHP2PY.!SUH)SR,&OC3]BC_@I%#\0H=)\)^,ENI/%-Q-'96]W!"SI
M?9X+L!]P@@YS7V3&`N3G.17CXC#U*%3DJ'R^-P=7"5?95(D]%%%8',%?"/\`
MP7/_`.">VM?MO_LZZ;JW@VQ^W>-_A_<S7=K9@&-M5LY-GVBW7N7+0QR(!DDQ
M!1]_G[NI"X"@DC![YXH`_D*U+3;G1M2N+*\MY[6\LW\N>":,QRPM_=93RI]C
M7JG[/?[>?Q?_`&4)5A\`_$;Q)H%E`"PT\3?:-.4C[I%K+OMU`_N^77]"G[6/
M_!+OX(_MG3/>>,_"%NFO3)C^V]*=K#4<]<F1!B4\'_6!^E?!OQO_`.#6N1DE
MF^'/Q5)4_P"IL/$M@3C_`'KF'/\`Z(H`\L^!_P#P<Z?%[P8\-OXY\*^$/&UM
M'_K)8#)I=Y+_`,#0/$O_`'YK[*_9C_X.+O@E\;=1M-*\5Q:W\,]3G/EJ^J8N
M-/+8ZFZC/RK[RHHK\P?C_P#\$/\`]I']G^QN+ZZ\#2>*M+MAEKOPU=#4RP]?
M(4"X_P#(-?)DT3V\\D4BLDL3%71AAD(Z@CL10!_7AI&N67B#2;34+"\M;ZQO
MXEFMKFWE66&YC9=RNC*2&4KR""01S3-0TV#5]/GM;N".YMKB-HI(I8M\;H>&
M0KW!'KUK\-?^#?#_`(*"Z]\)_P!H&Q^#.NZA/?>#/&LDJZ5%.[RC1K_;O0(S
M'/ES$[67H93E?EK]UZ`/YK?^"NW_``3YN?V!?VHKJTTRTF_X0/Q:7U'P[<$%
M@D8D#26;-TW0L1[E"#T->&_`#]I/QC^RYXPO]=\%:Y<Z+JNHZ9<Z3<RP`KN@
MFBV$<_+OC^\C?WNG-?T=?\%+?V'[#]O/]E_6O"$H6+Q#:?\`$P\/7[1C=:7R
M(P523C$<BLT;<XQ(3U2OYE+ZSGTO4;JVG"0W-HQMG"_,-P."?P(-`#%<L59M
MSL'WG]YF0MG#L2?O<U^ZO_!OK_P3R3]G?X*-\5O$]B8_&7Q`@"Z;'-$1)I6E
M;@4)##*RW#!9&'4*(U_A:OSE_P""+O[!4?[='[5L,>MPQR^"/`JQZQKT>[`U
M`B0_9[4+UVN58,>\0*_>%?T916PL[5888T1$"HBA,(BCC:`.B@=*`+=?S4_\
M%L/^4HWQ@_["-O\`^F^UK^E:OYJ?^"V'_*4;XP?]A&W_`/3?:T`;_P#P1>_9
M.T']M;XS?$WX>Z^@CCU7X>7SV=Z!ODTN^74=.,-TGT9CD?W1VZU\S_'#X+^(
M?V>/BUKO@CQ;8"Q\0>&;Q[.Y@7(565@1*I/WHV1@P8<%2".#7WA_P;`_\G[^
M+_\`L0;S_P!..G5]/_\`!PW_`,$Z!\8/AJ/C7X3T\OXH\(P>7K\,$>YM1TU2
M0)L#DO#N;)Q]R0D\)0!F?\&[G_!1;_A97@8_`SQ??Y\0^'+<3^&9[B0;]0L0
M"TEKN)R[P@Y7&2T<F1PF1R7_``=<,-OP&Y'(\0_^XNORC^%'Q4U_X(?$;0O%
MOAO4)-.UW0KT7MG=(VTHZG<"1W1AP5_N^U?>W_!;K]L;1?VY/V:?V:_'^B^7
M;O>+K]MJM@KB1],O%&EK-;''3KN&?X<&@#XO_8V_Y.X^%7_8VZ5_Z605_5M7
M\I/[&W_)W'PJ_P"QMTK_`-+(*_JVH`*_G8_X.$/^4H_C;_L':5_Z1P5_1/7\
M['_!PA_RE'\;?]@[2O\`TC@H`Y#_`((G_P#*4;X/_P#81N/_`$WW5?TK5_-3
M_P`$3_\`E*-\'_\`L(W'_IONJ_I6H`*_EY_X*?\`_*0_XV?]C;J'_I0]?U#5
M_+S_`,%/_P#E(?\`&S_L;=0_]*'H`Y?]D3]K_P`;?L1_%>7QEX#GTVTUJ33Y
MM.+WMFMRHAD=7(P3]X;`<5]0_P#$1=^TQ_T%O"7_`((8_P#&O"/^"<G["EU_
MP4&_:!G\!67B2'PK+!I,VJF[DL?M<;>6T2,NT.IR=]?=O_$*OKW_`$6+0_\`
MPFI/_DB@#PG_`(B+OVF/^@MX2_\`!#'_`(U\O?M=_M?^-OVW/BO%XR\>3Z;>
M:U'I\.G![*S6V4PQNS@8!^\=Y.*_1?\`XA5]>_Z+%H?_`(34G_R17PE_P4;_
M`&%+K_@GS^T#!X"OO$D/BJ6?28=5%W'8_9(U\QI45=I=CD;*`&_\$P/^4A_P
M3_[&W3__`$H2OO#_`(.I_P#D?_@S_P!@[5?_`$9:U\'_`/!,#_E(?\$_^QMT
M_P#]*$K[P_X.I_\`D?\`X,_]@[5?_1EK0!^4.C:K/HNLV%[$BM-:W22`-]W*
M<_SX^M?I?_Q%%?%[_HG?PY_[YO?_`(_7YJ:!IIUWQ#I]AN"F]GBMPQ/"LTG)
M_7]:_5G_`(A5]>_Z+%H?_A-2?_)%`'(_\117Q>_Z)W\.?^^;W_X_1_Q%%?%[
M_HG?PY_[YO?_`(_77?\`$*OKW_18M#_\)J3_`.2*/^(5?7O^BQ:'_P"$U)_\
MD4`?I;^P!^T-J_[6/[('@OXBZS8Z?IVI^*+>6:6TL2PMX=ES+%A=S,>D>>M>
MU5Y!^P]^S7<?L@?LM^$/AQ=:K'KTWA:U>%]1CM/LZ76^:64_N]S$<R&O7Z`/
MC_\`X+R_\HH?BK_W"O\`T\65?SAU_1Y_P7E_Y10_%7_N%?\`IXLJ_G#H`_H\
M_P""#7_**'X5?]Q7_P!/%[7V!7Q__P`$&O\`E%#\*O\`N*_^GB]K[`H`^/\`
M_@O+_P`HH?BK_P!PK_T\65?SAU_1Y_P7E_Y10_%7_N%?^GBRK^<.@#]N/V;?
M'\_PP_X-C+O5K666.8>&M?L$D3/F1?:=7O+8LO\`M`RY'X5^(]?M/\%O"<WC
M3_@UUO;*!FWPZ'K=\0HR=MMKMW._X`1$GT`-?BQ@\=>5W?AZ_2@#]Z?^#:WX
M9VO@_P#8+N_$?V=%U#Q=XBNYI9RI#/';@01KGNJLDY_X&:_1.O@/_@W$\?VW
MBG_@F]::6KQ^;X7\0W^G3C<"07*70)],BX'7UK[\H`*S-4\/67B`1B\LK6\6
M,DJ+B)9/+[?+N!QG`S6G7EO[1_[7'PW_`&2?#^G:I\2?$UGX7L-6N3;6LUQ%
M),;B48R,1(^`,C)]Q0!VZ_#W0U8G^Q=*0K]QEM4W#]*VRP`))Z=?:OE9?^"V
M?[+;C(^+>CGITL+WN<#_`)8^M?3^GZC%J=A'<P,KQ3C<#G@CUH`M4444`%>"
M?MI^`#?:79>([=`)+`_9[IL<"(C<&)[*#W/%>]U1UG1H/$&G7%C=PK-:7$?E
MR*PX84`?)'[/]A>ZVVJV5G9M,L*"YX);!)VCI]#7T%\'O$S+"^B79,=S;G<@
M?Y25],'O7`^%/`]]^S?X4^)&JR8D6SM#/I]SCEU2)WVX_P![`KB_A5^UEJ>J
M:7:WMRMKKL2'83(H6>$^F\<$U\MQ%QE@<IQ,,/BW\1@ZMFJ;/K'=UYZ=?:G$
MX[YS7F'A+]J7PUXA1DN;E]*EQ\PN0%B7ZN.!^=>D6M[#J%LDT$T<T4@RKQL&
M5A[$=:]/+LYPF/I^TP=137D;W+-%&[WHS7K7`****`"BBB@"&-MPKG_'_@N/
MQKX:O=/D@MIA<0ND:W,9D@1L<%@"&//H:Z!".<4[/;N:7MK,NG4Y9>TIGY-_
MLI?%7X?Z)^W$L?BC4+?X?>)O"5S>P:KX=U1W\J:Y6%DW65T<)*CEED6.4AF#
M9_>C!K[G_P"">'[;&E_MV_LUZ/XXM;>+3M4E;[)J^G"4.;"]51O3KT8$.N>J
ML",]:_+7_@X$^"]KX9_;$.M6\+HOBC1X=18@E<7$#/#(RMQR51.GJ/6E_P"#
M>/\`:'NOA-^UG?>`+FY>+1?B):MLB9LQK?6T;2JX[`M&95/^ZGM7A5N(JTL?
M]7Q/33_Y$_I'/_#3#YEPC_K5@:C<^2$G'LHZ5%]^I^Y5%('!&<@TNX>M>\?S
M6%?@1_P6A_::^-WP&_X*,^/-'T/XJ?$CP_X?N&L;_2[+3/$M]8VJ0R6<`8*D
M;A<>:S#@XR#7[[U\!?\`!;S_`():WO[<_P`/-,\9^"[2*3XD^#(F@AMY3L37
M;`DR-;Y_A=7)9"><F1?XEH`_.S_@DU_P5!\<>`/VX/"Z_%3XK>-M=\&:]%)H
MU\?$'B"ZO;.QDE0"*=EF=D15E$>YR0%5I">`:_H.6X1U5@ZL&7<""""/7Z5_
M(KXB\.:KX*\0W>F:O8WVCZOIK_9Y[6Z@>">"7T9&`93[$5[_`/LY?\%;?V@?
MV6/#MMHGAGXA:C+H5G'LBL-4MHM2@B3^ZIE5I(_H,T`?TSE=RD;5^<X(/(85
M^`G_``<:>'?!FB_MXVTGA9=-AU2ZT&"X\2+;*KA;YKB95\Q1P)B@1B?1@3US
M7#?$?_@O-^T[\1M)GLU\<VV@P3_ZU]'TJUMIC_NN8_,7_OJODS7M?U'QAK-Q
MJ6J7EYJFJW,VZ:YN[DS33,?O!I#\^?[O%`'L/_!-+1+SQ%_P4)^"5OIX+W*>
M,-,NV*O@M!#=)+,..H\OD^@YK^HROR7_`."!'_!*K7_A7X@7XW?$G2+O2-5%
MJUOX7TF\7_2(5=#')?S1D!HY#&[QJA`.#(W1D-?K10`5_(Q\0/\`DH.O_P#8
M1N?_`$8_^(K^N>OY&/B"<_$+7AG).H7!_P#(E`'ZH_\`!JQ_R/\`\9O^P=I7
M_HRZK]EJ_&C_`(-66`^('QE!/)T[2A_Y$NJ_9>@`K^:G_@MA_P`I1OC!_P!A
M&W_]-]K7]*U?S4_\%L/^4HOQ>/\`?U"V*^__`!+[6@#W?_@V!_Y/W\7_`/8@
MWG_IQTZOW1N].CU&SEMKB&.>&9#%)&T>8W1^'0@\$$5^%W_!L"P_X;W\8<_=
M\`WF?;_B8Z=7[OT`?S=?\%C/^">MQ^PI^TM,^DVI'P^\8N]YH$HRWV,YS/9D
M]"8F^Z.I6ODP7UU=::L#2SO;H[SQPM(?*1Y$C5Y`O\);RX\G_9K^GW_@H'^Q
M-I/[>'[-.O\`@G54A@U*2-KK0=0,0!TR^1/W<OKM8G:P[QDCK7\S'Q/^'FM_
M"7Q]K'A?Q/ISZ;KV@7<EE>6LP/F6\HDPV#W!7E?4<B@#K/V-O^3N/A5_V-NE
M?^ED%?U;5_*3^QM_R=Q\*_;Q=I0_'[9!Q7]6U`!7\['_``<(?\I1_&W_`&#M
M*_\`2."OZ)Z_G8_X.#\G_@J'XW?JJZ?I0)[#_0X:`.0_X(G_`/*4;X/_`/81
MN/\`TWW5?TK5_-3_`,$3_P#E*+\(3_<U"Y+>W_$ONJ_I6H`*_EY_X*?_`/*0
M_P"-G_8VZA_Z4/7]0U?R\_\`!3_G_@H=\:SUW>+M1`]S]H?C]10!](_\&T__
M`"D0O/\`L4M1_P#2BUK]]:_`K_@VI!3_`(*'WA.1CPCJ)Y]/M%MS7[ZT`%?@
M5_P<L?\`*1"S_P"Q2T[_`-*+JOWUK\"O^#E8%_\`@H?9D9.?".G'CT^T7/-`
M'S=_P3`_Y2'_``3_`.QMT_\`]*$K[P_X.I_^1_\`@S_V#M5_]&6M?!__``3`
MX_X*'?!0G^'Q=IP/L?M"<?H:^[_^#J9@?B!\&AG)&G:J/_(EK0!^6'P^4M\0
M=!(!.W4;?..V)$)_(`_E7]<U?R"0RM#LD1I8F1<HR@[E?UKK/^%_>/O^AW\8
M_P#@ZN?_`(N@#^L^BOY,/^%_>/O^AW\8_P#@ZN?_`(NC_A?WC[_H=_&/_@ZN
M?_BZ`/ZSFD"$!F`)Z9..^/YFEK\4?^#:'XG>(O'7[5GCV'6/$.MZO;Q>$?,B
MCOKJ2X17^VP#S%4D\X[BOVNH`^/_`/@O+_RBA^*O_<*_]/%E7\X=?T=_\%Y)
M`W_!*/XJKN!;.DC&>>=8LL5_.)@^]`']'G_!!K_E%#\*O^XK_P"GB]K[`KX^
M_P""#<@7_@E'\*E+#=G5AC//&L7N:^P:`/C_`/X+R_\`**'XJ_\`<*_]/%E7
M\X=?T=_\%Y)`W_!*/XJKN!;.DC&>>=8LL5_.)@^]`']$O_!$_P`'6'Q`_P""
M-WP\T'5H/M.FZS:Z[8WD1&1+%-JVH1N/Q#FOP9_:D_9^U?\`99^/_BSP#KRN
M-0\.:B]L'V%1>Q[_`-W<KG^"1/F..%'/2OW\_P""#<@7_@E'\*E+#=G5AC//
M&L7N:Y'_`(+&_P#!)9/V^/!L?BSP@J:?\4O#ULT%KYC+%!KT`;*VT['H5/SQ
MN?NGY3QT`/S5_P""&O\`P4;L/V(/CU?Z'XNO)[;P'X[V6]W=2?.NEW<;.8IR
M!T4[Y5=NRNF>$K^@[1=?L?$FDVU_IU[::A8WD8F@N+:9989T/1U920RGU!Q7
M\E'Q'^%WB'X4>-M0\.>*M$O]"U[299(KFPOH7C>VV_Q@$`D-V/>N[^!'[<WQ
M@_9KL(;+P+\1_%WAZQ0%H]-AU!GL<KT*P-F,`_W0M`']4D]U';0O)+(D<<8W
M,S,`JCU)/05_/S_P7Q_;]TO]K[]HK3?"OA34TU7P9\.[>>%+^W=9(-2OI?\`
M731,N5>+8BQJP)!SN!KYY^.?_!1;XY?M$^&WTKQK\3O%.KZ1-'Y<UEYPMK:X
M'_36*+9')_P)17D/ACPWJ7C;Q+9:1HUI>:MJ^JR>5;6MM"T\]R_]U$4%F;V`
M)H`]$_8M^`%[^U;^U7X'\`P1-*/$>JQ)>E4(\JT4[[A^.@6'G/0&OZHK>#[+
M`D8C5`GRJJCY5%?G[_P1(_X)/7'[%'A>Y\>^.[:+_A9GBBU$0MQ'Y@T"U9MW
ME[S]Z>3[SL/NGY?:OT)H`****`"BBB@#RC]L1-2NOV<_$=KI%G>:CJ%W'';I
M!:PM-*ZO*B.0J@D@*S$^@!-?`S?\)#^S[XMCM->TR_L'N8_.DM)T0ET?^)&Z
M$KWQTK]1FMP0`ZEN?3-<5\:/@+H7QW\)R:5KUBDJ*NZ">-=LUK)_>C;&1]#7
MYSQKP2LX7MXR]^,?AZ?>>;CL$ZT_:0E9H^/M`\60ZM:P:A8S"9-WF`LN3G^X
MR]C['FOIGX$_M(:)XJT^#2+A+32+Q%$<440\NWF;T3^[]#S7QA\9?@'XX_9)
MU]KX>?JOA]G^6^$;>3*OK,H_U9^M'A?XH6/C>&)8IWBO0/FMY&P_F>JXY/X5
M^/95F&9\,8V3G3TZQ[_,\^&/>'TK;GZ8Y&T\]*<L@SUSFOBSX:_M:>(/ABUO
M:W4IUK3(URL$S;9@/]F0\`?[U?0OPS_:H\*?$=4A^WQ:9?-]ZWO2(F;_`'6)
M`;\*_=,CXVRW,(<L)<D^TM_O/8I8ZE4ZGJ-%,2XCD`*R(V>F"#FG>8I!.X<>
M]?9*2>J=SJ%HIOG+TW+GZTN\>HIMV!D"NK]"`1SCH?K3+F&26WE1&(=ONGTK
M(N/'^DVGB^+P_)J,$>LSVYNTLRZJ[Q@X+`=2`<9->,?MG_MU^'OV5?"$T5K)
M::WXJN1BTTN)]Q#XX:4KS&ONV*Z\'@,1B:L*5*%Y2/'S+/\``Y;AIXK%58QC
M#?5;KIZ^1^4__!4KXB^/_$_QX?PU\0/L\FK^!X)K"&\MD\E=5MW;S(KE@/N[
MHNW3->#?L3ZS-X(_:_\`A;JUM)+&+?Q5I\1*`[G22<12C_@2.17UM\5=#\2?
M\%'_`-F^+6[*V/B+XR>!;DV>HVL0"7.NZ5<S%HI1&O!,,N%8CA4'.!7-_`'_
M`((^_'^3QSH>N)I>A>$-0TB[BU"SDUV_1PSQ,LG,4/FG.0>W:OSSB+AW,L#G
M<\/5@WRRW/[R\-?%G@[/O#*C4C6IT.>E.GR-V?/U=M]3]P+:0/".1D=1WIZ@
M@FN4^$UEXF@^'^GQ>+ET=]?CA"77]DB6.S+>L:R#<!]:ZW!]Z^Z>FA_%$XJ,
MY10^BBL;Q3\1?#_@:2W36]=T;1WN@YA%]>Q6YF";=Y7>PSMW+G'3<,]14D'E
M?[4'[`GPF_;#MR?B!X#TC7+V--D6HH'M=1A&.-MQ$4D/;Y2VWWKX^\9_\&PW
MP:UV:271O&7Q(T.0CY(9;JUO((OIF!7/_?=?H;X?^+?A3Q;J(L]*\3^'M3NR
M"1!::C#-(0#C.U6)ZUT&\9`R,GB@#\P_"_\`P:Z?"FRN%?6?B#\0-31?O+:B
MUM-W_?4<E?47[,/_``2+^!7[)NKVNJ^&_`]I?^(+%5^S:QK<K:E=V[C^*,2?
M)#_VR"U]-T4`5?LQ1E`0'"[22,!5_N@"K5%4?$/B?3?".E2W^K:C8Z990%!)
M<7<Z011EG"*"S$`;F95&3R2!U-`%ZOBK4?\`@@'^S'JM]<W4_@S6S-=2/(S#
MQ#?#EOF/_+7UK[2AN8[B%)(Y$DCD4.K*P*L",@@]P13Z`/"?V1?^"=?PL_8:
MU#7KKX<Z-J&E3>)$ACOS/J5S>>:(MY7'FNV.7->[444`%?*7QU_X(T?`7]I#
MXOZSX[\6^$]2U#Q'X@=)+ZYBUR\MQ(4A6(85)`!P@KZMW#CGJ<5QOB7]HSX>
M^#/$CZ-K'CSP;I6L1LJ-8WFM6T%RK-]T&-W#`GL,<T`>2_LI?\$M_@Y^Q5\2
M[KQ;\.M`U'2-:O\`3'TJ>6?5+F\5X'ECD(Q*YYW1+7T94<-Y%<1H\<L<BR*&
M0JP(8'H1ZBI*`"OF']I7_@D=\#OVM/BG-XU\;^$;F_\`$=W;):W%U::G<V(N
M`APA98G7YL=6]!7T]10!\:^"?^"$'[-WPT\;Z)XBT?P=J\6J>'KN&^L96U^]
M812PNLB$CS.>4%?95%9^D>+M*U^^O;6PU33[ZYTV7R+N&WN4EDM9.?DD522C
M<'@X/!H`T*^7OVC/^"0_P-_:S^+=_P"-_&_A?4]1\1:A'%%+=1:M<VRD1+Y:
M_*DB_P`*C]*^H:*`/E+X%?\`!&CX"_LW_%_1O'?A+PGJ6G^(_#[O)8W,NN7E
MP(R\+1'*O(0>'-?5M%%`!7R-\5_^"(_[/7QI^)>N^+_$GA35;W7?$EU+>W\R
M:Y>1+++(^XD*C\<^E?7.[WKG?'?Q?\)_"V&"7Q/XH\.^'8[DXA?5-2ALUE//
M"F1AGH>GI0!X;^RU_P`$IO@O^QG\3I/&'P_\-:EI6NRVCV)FGU>YO%\J1U9A
MB60]T%?2E97A/QUHGCW1(]3T/6=*UK3IAE+JPNX[F!Q[.A*G\ZU:`"OFO]J7
M_@E-\%_VS/B='XP^('AK4M5UV*T2Q$T&KW-FOE1NS*,12#NYKZ4HH`^1OA1_
MP1'_`&>O@M\2]"\7^'/"FJV>N^&[J*]L)GUR\E6*6-]P)5WYY]:]#_:Z_P""
M=?PL_;EU#0;KXC:-J&K3>&TFCL#!J5S9^4)=A;/E.N>4%>[5'<7L-I:R3RS1
MQPQ(9'D=@J(H&2Q)X`QWH`^*O^(>_P#9;_Z$C6O_``H[[_X[1_Q#W_LM_P#0
MD:U_X4=]_P#':^IO"7[1WP\\?>(1I&A>//!FM:L<_P"A6&MVUS<<'!_=HY;C
MZ5V2N&!((.#C@]Z`/B?_`(A[_P!EO_H2-:_\*.^_^.T?\0]_[+?_`$)&M?\`
MA1WW_P`=K[9HH`^??V3/^"9GPA_8A\::GX@^'6@:AI.IZS:_8KN6?5+F\$D6
M]9,`2NV/F05]!45#?:C;Z7937-S/#;V]NC22RRN$2)5!+,Q/```))/0"@#AO
MVD/V=_#'[4_P<UGP%XTLKC4?#.O^4+ZVAGD@>;RIHYD`=""/FB7H>N*^9?\`
MB'O_`&6_^A(UK_PH[[_X[7VAI.MV>OZ;#>V-Y;7MG<+OBG@E62*1?564D$>X
MJS0!P'[-_P"SOX8_98^#FC>`O!EE<:=X9T#S18VTT\D[P^;-),X+N23\TK=3
MUS7?T44`<!^TA^SOX8_:G^#FL^`O&EE<:CX9U_RA?6T,\D#S>5-',@#H01\T
M2]#UQ7S+_P`0]_[+?_0D:U_X4=]_\=K[9W#&<URGCOX[^!_A=J$-IXG\9^%/
M#MW<#,4.J:M;V<D@XY59'!/4=/44`9?[-_[._AC]ECX.:-X"\&65QIWAG0/-
M%C;33R3O#YLTDS@NY)/S2MU/7-=_532->L=?L+>[L;VTOK6\C\V":WF66.9.
M/F5E)##D<CCD5;H`\F_:._8C^%O[76EI:_$;P1HGB@P?\>US<1^5>6O'_+.X
MCVS)^#5\9_$+_@V/^"WB6_N)]!\6?$#PXLW6U^T07=LG^Z'B#_\`C]?I+10!
M^8W@_P#X->OA+I5S%)K'CCQ]J:)+YA@M3:V2D>F1&U?8W[+O_!/;X3?L:QLW
M@'P38:;J,L>R;5IF:[U&7M_KI2SCC^%<+7N=8'CSXK^%OA7:17'BCQ+H'AR"
M<[8Y-4U"&S20^@,C*">1T]:`-^BLOP?XXT7XA:##JN@:QI>N:9<9\J\T^ZCN
MK>3'7:Z$J?P-:E`!1110`4444`%%%%`&?J^AVVLV36MW!!=VTOWXYD#JWX$8
MKY'_`&B?^"6.F^*IY]4\`W2>'K\_/_9\VY[&4^B8YA/^[FOL,`@=<FEVDC!S
M7C9CDV%Q]+EQ4+K\?O.;$X*E75JJN?DEXNO/'W[.FI'3O''AZ]AB4[(;B0G;
M<#_9E4;6_`U;T+XKZ#X@0I:WD4$YZP3$Q$_[@/RG\#7ZG^(/"ECXMTB2QU.Q
M@OK6<8D@GB62-OJ",?E7S+\8/^"2?P[^(7GW.AM>^#KZ8?\`+DQFM'/^U"W3
M_@!CK\JS?POJ^T]K@9GS^+R:M'^`[GS]X4^-/BCX:/&=#U^\LX$Z1!R8C_P!
M^/UKT/0?^"AOCG1RHO(=(U2-.K26\D;M]"C8KRSQ[_P2O^-7PN)D\(:OI_B6
MTB_U$%O/]EF_X%'-B+]:\@\9^#_C;\+Y]NN>`M:"P=9I-)DE@?Z31@I^M>/#
M#\19:_9TY27W_P#!/"K2S/#_``J1]I?\/2M1@M=K^#;6:7NR:JT8_6%J[+]G
M/]NG5_C_`/$JVT2'PE#I]NEN]S=7)U'[08(QPN!L7))K\M=3_:.U'3YO+N-+
MM()/[LBLK?D:]'_9C_X*:S?LYZGKB:AX,M=9M]8$<<Q@OFMKB!`""H;#<'/:
MOHLCS_-ZF,A''5&J2W=C3!9QCY5(>U^$](_:O^,][X__`&G=;\0:5=WEG+I;
M/IUC-:/Y$BQ1C:=CCD;VY&1R!Q7S[\1?$UEH227-S/)=7I'RJ2SNX_VB?N_C
M7O'@#X;?"W]L;5(K?X=>+_%GA34KE!C2M=THW$`D]5N8`44?5JX?X[?\$Z/B
ME\(YIYY?#%YK.G1'8]YHQ:^R/7RP!+^E?W3PIQ!P]B,-"&&JQ4HQY=59_>S^
M1>*^".+YXZKB\PIN=*<W.\6W'WOZ['R%_P`+4\;>"O'-WJOA'7=<\/ZMJ47V
M3S=&GDMKB:+?N\E2C!CSW`K]:O\`@CY^P+XG_9W\-ZK\1?B7<ZO?_$KQK&(7
M&HW#3W&E6((987)/$DC`.^&RI$:_P-72?L#_`/!.[X6?"W0]*\>64B>-M<NX
M5NK;5[Z($6S'D^5`R_NG5L@EAY@(P<=*^P2I"J`#D^W%?GO&O%E#,*DL-@XI
M+K*VK/Z=\-.",3EE"-;&RLU\,$]$N[\RQ1117YX?KX5^;'_!;]?!!_:[_9*7
MXD_V:?`9U?71K7]HDBT6'R]/^_MP2/<U^D]?F[_P6P^(7A#X2_MG_L@^)?'E
MQ;V_A/0]6URXU-KBUDO(TB,=@`IA2-R^<'MV-`'@_P"WQHW[(&J?"33X_P!G
M,Z./CE<:K96W@_\`X1*:]CF,S7$8D$AW")8_)9\E^-P^M?K_`.#K?4;?PAI<
M>M21W&KPVT27K(<(UP(QN(]B3_*ORY_;Z_;4_9*_:I_9H\2>"_AIH.E^/?B/
MK,*6?AZTT7P+=0:A;W9?]W+%(]K&2L74HOS$#ISFOT=_97\)^)/`7[,_P]T3
MQ?+]J\4Z-X<L++5I0_F"2ZCMT27YOXLN"=U`'HE%%%`!7QU_P7C5X_\`@E)\
M4WX+#^ROF"?<_P")Q9=.0:^Q:^/O^"\\JI_P2C^*BE@&;^RL`GD_\3>S/\@3
M^!H`^I_A\2W@?17;DMIUO_Z+%;58WP]X\"Z(#U6P@4CN"(P"/J#6S0`4444`
M?(__``64_:+\1?LW_L:S)X,G-GXM\?:Y9^$=)NT;RA8RW6XO+N[$10R!?]H@
M=:B^$O\`P1:^`7@/X16_A[6_`FB^+]2EMPNJ:YJ2RRZAJ-PP^><3;]T6X]`F
M-M:?_!73]ECQ-^U5^R%<6/@V!)_&G@W5[;Q3H%N#L^T75KY@";CP2T<K8'=N
M*Y'X=?\`!=3X%WOPV2_\>>(+WX?>+[&$1:QX9U'2KP7UA=`#?"BB+<XS]T@<
MT`8G_!,K4-;_`&9OVPOC'^S/>ZOJ.O>%/!4%KXB\'7%_,9I;"PN.7M6<_-)L
M:50#_LFOO.OA#_@F!X1\5?M`?M1?%O\`:9\2Z!JGA/3_`!]#!H'A+2]0B$-V
MNE6^T>=)'T^=H8F4]#N;%?=]`!1110`5\%_\$H1C]M#]LL@9'_"P(E'(`1?]
M*^4C/KZ"OO2ORE_9'_;_`/A!^Q-^W'^UA;?$WQ8WAF?Q#XZ:XT]6TF]OO/5'
MN?,8?9HI-H^92,]<CUY`/U:SG\**\+_9@_X*(_!_]M'7-3T[X:^+?^$HO-&@
M%Q=1_P!D7MFT<9..&N(HP3G'2O=*`"BBB@#G/B3XWMOA?\.?$'B6]622T\/Z
M=<:E<!0262"$R,!^"G\J_/S_`()D?L1>%?VV_ADW[0OQTTO3_B'XV^(]Y=7M
MG:ZFTD^GZ'8K/)#'!%;LQCR-K#./Y5^A7Q`\'VWQ#\#ZWX>OQ(;'7;";3KG:
M"3LF1HVQ^#&OSP_8+_;:T/\`X)L?#]OV>_VAKFZ\$:QX&N[N/0M;O+&9],\3
M:?+,TJ2PRHK*I7S6&W/"C;]X$4`7?BI\%;'_`()7_MZ_"#Q+\+(;G0OAW\;/
M$$7@[Q-X:CDE>QCO)3BUN8U;(B/+<#&=IK]'J_-S7OBW%_P5R_;Q^$4?PYM=
M1O\`X0_!#6/^$JUGQ9-82VEKJ&HPO'):VMN)0K,0Z)DXSM,G'!K](Z`"BBB@
M`KX`_P""@JW_`.V5^W]\./V8CJ^H:7X"DT:7QMXXBL+KRIM4M8YBEO;%T.Y`
M9HU+`$869&^\5!^_Z^"_^"BVE^(OV2/VW/AU^T_HV@ZCXE\(:7HTOA+QO9Z=
M&9;JQL6>62*\1%&7"M(=W8>6G/2@"/\`:[_X)O?LJM\,;KP?9S_#?X3>.].@
M6YT#5$U>'3-3T^Y4;H979G$CHQQN!!!&>M?4O[']UK-U^S5X-3Q!XK\.^.]<
MM=/%C>Z_HEW]JL]5DA8Q-*DO\1)5@QZAPP/((KXF_:L_;/\`V1OVC]$OK[PK
MX2\/_'#XN^(]-.FZ'I<'AB6XU">9T*0^:TL8$<:'!8'D`=!7M'_!"*-[/_@E
M%\+(G61+A/[5\U&8AQ_Q-[T\EN>A!^A%`'V)1110`5YC^V'N/[(OQ2.UPX\(
M:J<%L%#]CFY!']*].KS7]L>51^R5\4@6&6\(ZJ!SU/V248_,@?4T`>:_\$BE
MW?\`!-/X/.@(#Z#&X!W9_P!8_7G)KZ4KYO\`^"0S;?\`@FE\'5)PT?A^,,.Z
MG>_!]*^D*`"BBB@#R#]NCX_3?LM_LE_$'Q[:*DM]X<T:>XLXY.%:[91';Y[;
M?,*YKYJ_8$_X)9?#;Q1^SCH7COXN>&K#XE_$KXF:?#KWB#5M?_XF#N]TOG+'
M&),JBJCH"%_NU]-_ML_L_P`O[4?[*'CWP!`Z0WGB71IK:SEDX6.Y`W0%CZ"1
M5)KY+_8F_P""MGP]^!?P'T'X;?'>_P!0^%WQ(^&^G0:'J5AK&FW!%XMLODQW
M$+11L'#J@.!G.?>@#US]BC]@+5OV'?V@/'R^&M9M#\%O%*1WVF>&9I[B>YT/
M4`4WF(R9'E-E^0=WRQ\=*^L:^,/V!OVE?'G[:W[4/C[XB64FIZ;\`+73X]&\
M(V5_9);G6[TNLDNI(642!0!(H!!!\_'\''V?0`4444`%?D?XVU[X2_#S_@J1
M\8+W]K[1[N>+5Y[>/X>WVMZ?-=Z%%I2I(OEQK&K(&(=-SG/SKC((K]<*^`4_
MX*.:7\'/CO\`$?X5_M86UGI.G'79)_!NKWVA/<:/K.F,/W*EE1T\U5^\6``8
MGO0!O_L'?LU_#SP7^UKXE^(_[/WQ`\'WGPG\3Z,+;6/"VDZ@;U+751+N6Y4;
MV\@E?E*$*?:OM^ORO_9GA^''Q=_X*]>#O%W[,>CSV?P^T+PYJ">/]2TC3Y-+
MT&\D>*1+>)8W1%,HD:!^.<0KCB-S7ZH4`%%%%`!1110`4444`1T&5AUS156X
M=L]30!9,Y'6J_P#:@]/TJ"X=N>37'>*M0N;?.RXE7Z$4`=Q_:07J#^(J%=1)
M<D1?)CKO./RP:^8/BEXZ\060S!KVI0_[A0?^RUYQH_Q'\97NM>5+XT\1/%_<
MS`!_Z*IU%"WO(+GV[/;V5T<O;6TO^TT:DU5M_`6AZ?,[Q:+I,$TG5H[)%;\P
MI%>+_"[Q-K%[_K]9U&?_`'W4_P!*]B\.L]P?GDD;ZFL_J]/^5?<2X4_Y?P-F
M"&*)$58E7R^@4'/YC%66C60%7`.[[PVY!J&#O5@<>IJ5RQV0<GN^1!'9M%M"
M(J\G.&(*Y;)QQCFKI.<9SD5&CEL9[U(WRX[UM<SC_='4444C8*J^5LD4[9,K
MG)`&0../QQSBK5%`%80_NU!C8[#\JX7\QC@'\:LT44`%%%%`!5,P'S#E-^X@
MYP!@Y)STYP1D<=ZN44`1"/:JC8#M.U0.`!4M%%`!1110`5SVJ_#;0]4UJ/5+
MK0M'N]3@.8KN6RBDN(S_`'E<KN4_3-=#10!66$0*B+&Q4+@``<`=%'0`59HH
MH`****`"JR1-"@55&[[Q([GN1GO]35FB@"L]KN9LJ7+C##"[2,?=.>2*LT44
M`%%%%`!6/XB\':5XLLS:ZMIMEJMN3Q%=VJS1CV`92`*V**`*.FZ/;Z3;QP6D
M$5I;H?EABC"1I[@`#!^M7J**`"BBB@`J"2(S!E;YE8$'@C/M@@@BIZ*`,/1O
MA_HWAS4KB]L-%TNQO+D;IY[:TBBEN&QU+!03^-7X(BH)VN-W(`&!G.?08))R
M>.U7:*`"BBB@`JIY!DA*/&2DF592`>,XP1R"".M6Z*`*T406-0$QM3"``@*O
MH,`8_*K-%%`!1110`5A>(?`.B^+IH9M5T32-3>T/[EKRS2=X\=-I9<J?IFMV
MB@"O;6WV>%5VY"#Y5&`/P&`!5BBB@`HHHH`*R=>\(:=XLTXVFK:?9:I:$Y\B
MZMDFCQZ!6'!K6HH`S-&T&U\.V4=K96<%K:P\1PP0K'%%CIA0!C\,UIT44`%%
%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
